Integra LifeSciences Holdings Corporation (IART) SEC Filings & Earnings Calls

FDA Warning Letter and Quality System Issues

“On December 19, 2024, the Company received a warning letter from the FDA... The 2024 Warning Letter relates to quality system issues identified during FDA inspections at three of the Company's facilities” · word for word

Cincinnati Facility Flood Damage

“On July 17, 2026, widespread flash flooding affected the Cincinnati, Ohio area, which caused damage to the Company's Cincinnati facility, equipment, inventory, and other assets and has resulted in operational disruption to the site.” · word for word

Tariff and Trade Policy Uncertainty

“Tariffs have resulted in an increase in certain product costs and could have adverse impacts on, among other things, demand for our products and supply chains.” · word for word

High Leverage and Debt Covenant Risk

“The June 2025 Amendment... modified the Company's Consolidated Total Leverage Ratio... to 4.75 to 1.00 for the fiscal quarter ending September 30, 2026”

Cincinnati flood disruption continues to impact revenue and operations; recovery timeline uncertain.

“Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility... Our updated outlook reflects both the recovery timeline in Cincinnati” · word for word

Tissue Reconstruction segment softer than expected; guidance reflects more measured expectations.

“softer-than-expected results in Tissue Reconstruction... more measured expectations for portions of our Tissue Reconstruction business” · word for word

Increased interest expense from refinancing at 9.5% senior secured notes; higher leverage covenants temporarily.

“incremental interest expense associated with the refinancing... $450 million aggregate principal amount of 9.5% senior secured notes due 2033”

High coupon (9.5%) on notes suggests elevated credit risk or weak market access.

“9.500% senior secured notes due 2033” · word for word

Higher interest expense from 9.500% notes and broader refinancing

“Interest rate near high end of 100-200bps increase range previously communicated.”

Flooding-related supply disruption at Cincinnati facility impacting revenue and earnings; recovery timeline uncertain.

“flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption” · word for word

Potential asset impairments and unforeseen costs from flooding event.

“potential asset impairments, unforeseen costs and insurance recoveries” · word for word

FDA Warning Letter and Quality System Issues

“The 2024 Warning Letter relates to quality system issues identified during FDA inspections at three of the Company’s facilities... The 2024 Warning Letter states that premarket approval applications for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been corrected.” · word for word

Flood Damage at Cincinnati Facility

“On July 17, 2026, our manufacturing facility in Cincinnati, Ohio sustained flood damage as a result of severe weather conditions. The flooding caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruptions at the site.” · word for word

Ongoing Securities Class Action and Derivative Lawsuits

“On September 12, 2023, a securities class action complaint... was filed... The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs.” · word for word

High Leverage and Interest Expense

“Interest expense for the six months ended June 30, 2026 increased by $5.6 million as compared to the same period in the prior year primarily due to higher interest rates on the borrowings under the revolving credit facility component of the Senior Credit Facility as compared to the interest rates on the 2025 Notes, which was repaid in August 2025.”

Tariff Exposure

“In April 2025, the U.S. government announced new tariffs on goods imported into the U.S. from dozens of countries, including China and the European Union member states.” · word for word

Elevated leverage ratio of 4.1x and net debt of $1.6B pose refinancing risk in higher interest rate environment.

“Net debt at the end of the quarter was $1.6 billion, and the consolidated total leverage ratio was 4.1x. The adjusted EPS outlook reflects updated tariff assumptions, a higher interest rate environment, and potential debt refinancing actions.”

Tissue Reconstruction segment organic decline of 2.0% driven by product mix headwinds.

“Tissue Reconstruction revenues declined (1.9)% reported and (2.0)% organic, with mid-single digit decline in wound reconstruction.”

Foreign exchange headwind from stronger USD reducing reported revenue guidance.

“Updating reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates.”

Potential shareholder dilution from increased equity plan shares.

“Approval of 3,550,000 additional shares under equity incentive plan.”

CEO transition risk; potential strategy changes.

“Sudden CEO departure and appointment of former CEO.”

FDA Warning Letter and Quality System Remediation

“On December 19, 2024, the Company received a warning letter from the FDA... The 2024 Warning Letter states that premarket approval applications for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been corrected.” · word for word

Tariff Cost Pressure

“Tariffs have resulted in an increase in certain product costs and could have adverse impacts on, among other things, demand for our products and supply chains.” · word for word

Litigation Exposure

“On September 12, 2023, a securities class action complaint... was filed... The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs.” · word for word

FDA Warning Letter and Quality Compliance Risk

“We will continue executing our CMP to resolve our outstanding FDA Warning Letters and improve our supply chain resiliency, manufacturing excellence and process capability.” · word for word

Supply Chain and Product Availability Constraints

“product availability constraints that limited overall performance” · word for word

Tariff Impact on Costs and Operations

“The unanticipated tariff actions affected our costs, supply chain efficiency, and market demand.” · word for word

Operational Transformation Execution Risk

“This transformation is not solely operational, it is also cultural.” · word for word

CEO Transition and Leadership Turnover

“Strengthened our executive leadership team through the appointment of six new executives” · word for word

Reliance on non-GAAP measures; GAAP reconciliation not provided for forward guidance.

“did not provide a reconciliation to GAAP earnings per share, because certain GAAP expense items are highly variable” · word for word

FDA compliance and recall risk

“In May 2023, after consultation with the FDA, we initiated a voluntary global recall of all products manufactured in our Boston facility distributed between March 1, 2018 and May 22, 2023.” · word for word

High leverage risk

“As of December 31, 2025, our total consolidated external debt was approximately $1.9 billion” · word for word

Bovine tissue sourcing risk

“In 2025, 26% of our revenues derived from products containing material derived from bovine tissue.” · word for word

Healthcare reform and pricing pressure

“Government and private sector initiatives to limit the growth of healthcare costs, including price regulation, competitive pricing, coverage and payment policies... are continuing in many countries where we do business, including the U.S.” · word for word

Potential change in control risk; severance program may indicate M&A preparation or retention concerns.

“Program effective Jan 1, 2026, with two-year post-change-in-control coverage; CFO receives enhanced 2x multiplier.”

FDA Warning Letter and Quality System Violations

“The 2024 Warning Letter states that premarket approval applications for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been corrected.” · word for word

Goodwill Impairment Risk

“Goodwill impairment of $511.4 million recorded in the second quarter of the current year.” · word for word

Litigation Risk

“On September 12, 2023, a securities class action complaint...was filed...alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.” · word for word

Supply chain interruptions impacting revenue; Braintree facility restart delayed to June 2026.

“While revenue was impacted by two supply interruptions; Braintree facility remains on track to resume production in June 2026.” · word for word

FDA warning letter and ongoing quality system remediation create regulatory and operational risk.

“Continued constructive engagement with the FDA on routine inspections as well as warning letter commitments.” · word for word

High leverage ratio (4.3x) and net debt of $1.6B increase financial risk.

“Total balance sheet debt and net debt at the end of the quarter were $1.8 billion and $1.6 billion, respectively, and the consolidated total leverage ratio was 4.3 x.” · word for word